Should I Buy NAGE? NAGE 2026 Analysis

Should You Buy Niagen Bioscience Inc (NAGE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

5.200

1 Day change

1.36%

52 Week Range

14.690

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price is in a confirmed downtrend and just broke below the listed S2 support (5.186) with a -6.96% drop today.
Oversold (RSI_6 ~14.9) increases the odds of a short-term bounce, but there is no proprietary buy signal (AI Stock Picker/SwingMax) and momentum is still deteriorating.
With earnings on 2026-02-10 (after hours) and the stock already weak, risk of additional downside remains high; for an impatient buyer, this setup is unfavorable.

Technical Analysis

Trend/momentum: Bearish structure with SMA_200 > SMA_20 > SMA_5 (persistent downtrend) and a negatively expanding MACD histogram (-0.0746) indicating downside momentum is still building.
Oversold condition: RSI_6 at 14.931 suggests capitulation/oversold, which can produce sharp dead-cat bounces—but not a confirmed reversal.
Levels: Price 5.145 is below S2 (5.186) and below S1 (5.435), meaning prior supports are failing; overhead resistance/pivot sits around 5.838 then 6.241.
Near-term statistical bias (pattern analog): modest upside probabilities (+1.55% next day / +2.22% next week / +5.18% next month) but not strong enough to override the current bearish tape.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/sentiment: Open interest put/call ratio 0.63 and extremely low put/call volume ratio 0.03 show calls dominating—bullish/optimistic options sentiment despite the selloff.
Activity: Today’s options volume (251) is elevated vs 30-day average (176.76%), suggesting traders are actively positioning around near-term moves (likely into earnings).
Volatility: 30D IV 76.68 vs historical vol 40.06 implies options are pricing large moves; IV is also well below the 5D/10D IV averages (105.894/107.801), indicating IV has recently compressed but remains high.

Technical Summary

Sell

Buy

Positive Catalysts

- Fundamentals recently improved strongly (2025/Q3: revenue +32.86% YoY; net income +143.77% YoY; EPS +150% YoY; gross margin 64.52% +1.62% YoY).
- Upcoming catalyst: QDEC 2025 earnings on 2026-02-10 after hours; if results/guide beat, oversold conditions could amplify the rebound.
- Options market is positioned bullishly (call-heavy), which can add fuel to any upside surprise.

Neutral/Negative Catalysts

- Technical damage is significant: downtrend across moving averages + MACD worsening + breakdown below key support levels (S2/S1).
- Event risk: earnings in a few days can gap the stock; with price weak, a miss/soft guide could trigger another leg down.
- News flow provided is largely sector-wide/other-company related (functional beverages, other brands) and not a clear direct catalyst for Niagen Bioscience right now.
- Flows/holders: Hedge funds neutral (no notable accumulation); insiders neutral (no supportive insider buying trend).

Financial Performance

Latest reported quarter: 2025/Q3.
Growth: Revenue 33,986,000 (+32.86% YoY) shows strong top-line momentum.
Profitability: Net income 4,578,000 (+143.77% YoY) and EPS 0.05 (+150% YoY) indicate operating leverage.
Margins: Gross margin 64.52% (+1.62% YoY) improved slightly, supporting quality of growth.
Takeaway: Fundamentals look better, but price action suggests the market is currently de-risking the name into the upcoming quarter/earnings.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price-target change data was provided, so no confirmed recent upgrades/downgrades or target revisions can be summarized.
Wall Street-style pros (based on provided fundamentals): accelerating revenue growth, sharply higher earnings, and strong gross margin profile.
Cons: current tape is decisively bearish, small-cap volatility is high (IV elevated), and near-term direction likely hinges on the 2026-02-10 earnings outcome.
Influential/political trading: No recent congress trading data available; hedge funds and insiders show neutral activity.

3 Analyst Rating

Wall Street analysts forecast NAGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAGE is 16.33 USD with a low forecast of 12 USD and a high forecast of 23 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.130

Low

Averages

16.33

High

Current: 5.130

Low

Averages

16.33

High

Canaccord

Buy

downgrade

$16 -> $14

AI Analysis

2025-11-05

Reason

Canaccord

Price Target

$16 -> $14

AI Analysis

2025-11-05

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Niagen Bioscience to $14 from $16 and keeps a Buy rating on the shares. The firm said they posted a Q3 beat as they continue to see strong demand for the flagship TruNiagen supplement businesses, leading to total company sales up +32.9% vs. our/Street estimate of +22.6%/+22.0%.

H.C. Wainwright

Buy

maintain

$11 -> $12

2025-08-11

Reason

H.C. Wainwright

Price Target

$11 -> $12

2025-08-11

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Niagen Bioscience to $12 from $11 and keeps a Buy rating on the shares. The company's Q2 revenue and earnings beat expectations, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NAGE

Unlock Now

NAGE Should I Buy

NAGE Should I Buy

Should You Buy Niagen Bioscience Inc (NAGE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch